Chasing LDL cholesterol to the bottom — PCSK9 in perspective

Low-density lipoprotein (LDL) indubitably contributes causally to atherosclerosis, a leading challenge health worldwide. Interventions that lower LDL cholesterol (LDL-C) have made remarkable inroads against this global scourge. Recent therapeutic advances achieved ever levels of LDL-C. Improved cardiovascular outcomes continue accrue from these interventions. In particular, the discovery role proprotein convertase subtilisin/kexin type 9 (PCSK9) as causal gene in autosomal-dominant hypercholesterolemia has led with speed development novel agents LDL-C concentrations beyond prior measures, and alleviate further risk. We review how story, its position broader landscape therapy prevent atherosclerotic events, represents notable victory contemporary medicine reflects successful partnerships between basic scientists, pharmaceutical biotechnology sectors, clinical investigators. Continued cooperation manner promises yield progress combating diseases interventions on Libby Tokgözoğlu discuss management atherogenic lipoproteins, notably low-density lipoprotein, an emphasis strategies target PCSK9.